Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation
Marcus Robertson, Avik Majumdar, Kent Garrett, Greg Rumler, Paul Gow, Adam Testro – 31 March 2014
Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation
Marcus Robertson, Avik Majumdar, Kent Garrett, Greg Rumler, Paul Gow, Adam Testro – 31 March 2014
Inhibition of microRNA‐24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia
Raymond Ng, Heng Wu, Hong Xiao, Xin Chen, Holger Willenbring, Clifford J. Steer, Guisheng Song – 28 March 2014 – The incidence of nonalcoholic fatty liver disease (NAFLD) and hyperlipidemia, with their associated risks of endstage liver and cardiovascular diseases, is increasing rapidly due to the prevalence of obesity. Although the mechanisms of NAFLD have been studied extensively, the underlying pathogenesis and the role of microRNAs in this process remain relatively unclear.
A chronic disease management model for chronic liver failure
Alan J. Wigg, Mohamed A. Chinnaratha, Rachel Wundke, Michael L. Volk – 28 March 2014
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals
Liesl M. Hagan, Mark S. Sulkowski, Raymond F. Schinazi – 28 March 2014 – Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)‐ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks.
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals
Liesl M. Hagan, Mark S. Sulkowski, Raymond F. Schinazi – 28 March 2014 – Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)‐ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks.
A chronic disease management model for chronic liver failure
Alan J. Wigg, Mohamed A. Chinnaratha, Rachel Wundke, Michael L. Volk – 28 March 2014
Ending vertical transmission of hepatitis B: The third trimester intervention
Monika Sarkar, Norah A. Terrault – 26 March 2014
Bioactive compound reveals a novel function for ribosomal protein S5 in hepatic stellate cell activation and hepatic fibrosis
Wei‐Heng Xu, Hong‐Gang Hu, Yuan Tian, Shao‐Zhan Wang, Jie Li, Jian‐Zhong Li, Xing Deng, Hui Qian, Lei Qiu, Zhen‐Lin Hu, Qiu‐Ye Wu, Yi‐Feng Chai, Cheng Guo, Wei‐Fen Xie, Jun‐Ping Zhang – 26 March 2014 – Liver fibrosis and its endstage, cirrhosis, represent a major public health problem worldwide. Activation of hepatic stellate cells (HSCs) is a central event in hepatic fibrosis. However, the proteins that control HSC activation are incompletely understood.
Engineering liver
Linda G. Griffith, Alan Wells, Donna B. Stolz – 26 March 2014 – Interest in “engineering liver” arises from multiple communities: therapeutic replacement; mechanistic models of human processes; and drug safety and efficacy studies.